Abnormal Vascular Reactivity in Growth Hormone Deficiency
- 30 January 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (4) , 520-524
- https://doi.org/10.1161/01.cir.103.4.520
Abstract
The reason why patients with growth hormone (GH) deficiency (GHD) are at increased risk for premature cardiovascular death is still unclear. Although a variety of vascular risk factors have been identified in GHD, little is known regarding vascular reactivity and its contribution to premature arteriosclerosis. We assessed vascular function in 7 childhood-onset, GH-deficient nontreated patients (age 22+/-3 years, body mass index [BMI] 25+/-1 kg/m(2)) and 10 healthy subjects (age 24+/-0.4 years, BMI 22+/-1 kg/m(2)) by using strain gauge plethysmography to measure forearm blood flow in response to vasodilatory agents. The increase in forearm blood flow to intrabrachial infusion of the endothelium-dependent vasodilator acetylcholine was significantly lower in GH-deficient nontreated patients than in control subjects (P:<0.05). Likewise, forearm release of nitrite and cGMP during acetylcholine stimulation was reduced in GH-deficient nontreated patients (P:<0.05 and P:<0.002 versus controls). The response to the endothelium-independent vasodilator sodium nitroprusside was also markedly blunted in GH-deficient patients compared with control subjects (P:<0.005). To confirm that abnormal vascular reactivity was due to GHD, we also studied 8 patients with childhood-onset GHD (age 31+/-2 years, BMI 24+/-1 kg/m(2)) who were receiving stable GH replacement therapy. In these patients, the response to both endothelium-dependent and -independent vasodilators, as well as forearm nitrite and cGMP, release was not different from that observed in normal subjects. Peak hyperemic response to 5-minute forearm ischemia was significantly reduced in GH-deficient nontreated patients (17.2+/-2.6 mL x dL(-1) x min(-1), P:<0.01) but not in GH-treated patients (24.8+/-3.3 mL x dL(-1) x min(-1)) compared with normal subjects (29.5+/-3.2 mL x dL(-1) x min(-1)). The data support the concept that GH plays an important role in the maintenance of a normal vascular function in humans.Keywords
This publication has 18 references indexed in Scilit:
- Endothelial dysfunction in hypopituitary adults with growth hormone deficiencyClinical Endocrinology, 1999
- Forearm Nitric Oxide Balance, Vascular Relaxation, and Glucose Metabolism in NIDDM PatientsDiabetes, 1997
- Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.Journal of Clinical Investigation, 1996
- Effects of Insulin and IGF-I on Vascular Smooth Muscle Glucose and Cation MetabolismDiabetes, 1996
- NG-monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF- I: possible role of nitric oxide in muscle protein synthesis.Journal of Clinical Investigation, 1996
- Nitric oxide— biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosisAtherosclerosis, 1995
- The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediatorPublished by Elsevier ,1995
- Signal transduction and regulation in smooth muscleNature, 1994
- Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adultsThe Lancet, 1992
- Premature mortality due to cardiovascular disease in hypopituitarismThe Lancet, 1990